


Healthcare News Roundup: Biopharmaceutical
HSMN NewsFeed - 14 Feb 2020
Kleo Pharmaceuticals Elects CEO Doug Manion, MD, FCRP (C), New Chairman of the Board
Kleo Pharmaceuticals Elects CEO Doug Manion, MD, FCRP (C), New Chairman of the Board
HSMN NewsFeed - 11 Feb 2020
Encoded Therapeutics Expands Gene Therapy Leadership with Key Appointment and Promotion
Encoded Therapeutics Expands Gene Therapy Leadership with Key Appointment and Promotion
HSMN NewsFeed - 10 Feb 2020
Enteris BioPharma Appoints Gary A. Shangold, MD, as Chief Medical Officer
Enteris BioPharma Appoints Gary A. Shangold, MD, as Chief Medical Officer
HSMN NewsFeed - 10 Feb 2020
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
HSMN NewsFeed - 7 Feb 2020
Perrigo Announces Consumer Self-Care Americas Segment Leadership Transition
Perrigo Announces Consumer Self-Care Americas Segment Leadership Transition
HSMN NewsFeed - 5 Feb 2020
Ichnos Expands Leadership Team With Appointment Of Gabriela Gruia, M.D. As Chief Development Officer
Ichnos Expands Leadership Team With Appointment Of Gabriela Gruia, M.D. As Chief Development Officer
HSMN NewsFeed - 3 Feb 2020
Eisai Inc. Expands Leadership Team in the US with the Appointment of Two Key Leaders
Eisai Inc. Expands Leadership Team in the US with the Appointment of Two Key Leaders
HSMN NewsFeed - 30 Jan 2020
Histogen and Allergan Expand Cell Conditioned Media (CCM) Skin Care Partnership
Histogen and Allergan Expand Cell Conditioned Media (CCM) Skin Care Partnership
HSMN NewsFeed - 29 Jan 2020
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
HSMN NewsFeed - 29 Jan 2020
vasopharm Completes Patient Enrollment for Phase III Traumatic Brain Injury Trial (NOSTRA)
vasopharm Completes Patient Enrollment for Phase III Traumatic Brain Injury Trial (NOSTRA)
HSMN NewsFeed - 28 Jan 2020
John Quisel, JD, PhD Joins Disc Medicine as President and Chief Executive Officer
John Quisel, JD, PhD Joins Disc Medicine as President and Chief Executive Officer
HSMN NewsFeed - 28 Jan 2020
Lilly plans donation of 200,000 insulin KwikPens over next three years to support lower-income communities
Lilly plans donation of 200,000 insulin KwikPens over next three years to support lower-income communities
HSMN NewsFeed - 23 Jan 2020
iOnctura Raises EUR 15 Million in Series A Financing to Progress its Pipeline into Clinical Development
iOnctura Raises EUR 15 Million in Series A Financing to Progress its Pipeline into Clinical Development
HSMN NewsFeed - 20 Jan 2020
Armas Pharmaceuticals Adds Four Generic Injectables As First Launches of 2020
Armas Pharmaceuticals Adds Four Generic Injectables As First Launches of 2020
HSMN NewsFeed - 17 Jan 2020
SkinMedica(R) Launches New Instant Bright Eye Cream For Immediate, Visible Results
SkinMedica(R) Launches New Instant Bright Eye Cream For Immediate, Visible Results
HSMN NewsFeed - 17 Jan 2020
DURECT Corporation Announces Outcome of FDA Advisory Committee Meeting for POSIMIR(R)
DURECT Corporation Announces Outcome of FDA Advisory Committee Meeting for POSIMIR(R)
HSMN NewsFeed - 16 Jan 2020
Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team
Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team
HSMN NewsFeed - 16 Jan 2020
ANI Pharmaceuticals Announces FDA Approval of Potassium Citrate Extended-Release Tablets USP
ANI Pharmaceuticals Announces FDA Approval of Potassium Citrate Extended-Release Tablets USP
HSMN NewsFeed - 13 Jan 2020
CNS Pharmaceuticals Licenses DNA-Binding Agent from MD Anderson, Doubling its Drug Pipeline
CNS Pharmaceuticals Licenses DNA-Binding Agent from MD Anderson, Doubling its Drug Pipeline
HSMN NewsFeed - 9 Jan 2020
Ionis Appoints Onaiza Cadoret-Manier As Chief Corporate Development and Commercial Officer
Ionis Appoints Onaiza Cadoret-Manier As Chief Corporate Development and Commercial Officer
HSMN NewsFeed - 8 Jan 2020
Former Celgene Chairman and CEO Mark J. Alles Joins Antengene Board of Directors
Former Celgene Chairman and CEO Mark J. Alles Joins Antengene Board of Directors
HSMN NewsFeed - 8 Jan 2020
Revitope Oncology Appoints Steve Arkinstall, D.Phil., as Chief Executive Officer
Revitope Oncology Appoints Steve Arkinstall, D.Phil., as Chief Executive Officer
HSMN NewsFeed - 7 Jan 2020
IFM Therapeutics Appoints Michael Cooke, Ph.D., as Chief Scientific Officer
IFM Therapeutics Appoints Michael Cooke, Ph.D., as Chief Scientific Officer
HSMN NewsFeed - 6 Jan 2020
Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer
Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer
HSMN NewsFeed - 6 Jan 2020
Slayback Pharma announces investment of $50 million by The Everstone Group
Slayback Pharma announces investment of $50 million by The Everstone Group
HSMN NewsFeed - 6 Jan 2020
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
HSMN NewsFeed - 2 Jan 2020
Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China
Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China
HSMN NewsFeed - 2 Jan 2020
CF PharmTech Closes US$ 90 Million Financing Round to Accelerate Global Development of Respiratory Drugs
CF PharmTech Closes US$ 90 Million Financing Round to Accelerate Global Development of Respiratory Drugs
HSMN NewsFeed - 2 Jan 2020
Aridis Pharmaceuticals Appoints Michael A. Nazak as Chief Financial Officer
Aridis Pharmaceuticals Appoints Michael A. Nazak as Chief Financial Officer
HSMN NewsFeed - 30 Dec 2019
Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer
Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer
HSMN NewsFeed - 24 Dec 2019
Correvio Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events
Correvio Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events
